EVOLOCUMAB PHARMACOKINETICS AND ITS EFFECTS ON LDL-C AND PCSK9 LOWERING IN SUBJECTS WITH MILD OR MODERATE HEPATIC IMPAIRMENT.M. G. Emery,J. P. Gibbs,J. G. Slatter,L. Hamilton, S. M. Wasserman, M. Geller,C. DiasCLINICAL PHARMACOLOGY & THERAPEUTICS（2015）引用 1|浏览1暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
